Literature DB >> 21300470

High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors.

Nigel Brockton1, Joseph Dort, Harold Lau, Desiree Hao, Sony Brar, Alexander Klimowicz, Stephanie Petrillo, Roman Diaz, Corinne Doll, Anthony Magliocco.   

Abstract

PURPOSE: Head-and-neck squamous cell carcinoma (HNSCC) is the fifth most common malignancy worldwide. Alcohol use and tobacco use are the most established risk factors; however, human papilloma virus (HPV) infection is a major risk factor for a subset of HNSCCs. Although HPV-positive tumors typically present at a more advanced stage at diagnosis, they are associated with a better prognosis. Tumor hypoxia confers poor prognosis and treatment failure, but direct tumor oxygen measurement is challenging. Endogenous markers of hypoxia (EMHs) have been proposed but have not replicated the prognostic utility of direct oxygen measurement. The expression of endogenous markers of hypoxia may be influenced by oxygen-independent factors, such as the HPV status of the tumor. METHODS AND MATERIALS: Consecutive cases of locally advanced HNSCC, treated with a uniform regimen of combined radiotherapy and chemotherapy, were identified. Tissue microarrays were assembled from triplicate 0.6-mm cores of archived tumor tissue. HPV status was inferred from semiquantitative p16 immunostaining and directly measured by use of HPV-specific chromogenic in situ hybridization and polymerase chain reaction. Automated quantitative fluorescent immunohistochemistry was conducted to measure epithelial and stromal expression of carbonic anhydrase IX (CAIX) and glucose transporter 1 (GLUT1).
RESULTS: High stromal CAIX expression was associated with significantly reduced overall survival (p = 0.03) in patients with p16-negative tumors.
CONCLUSIONS: This is the first study to use quantitative immunohistochemistry to examine endogenous markers of hypoxia stratified by tumor p16/HPV status. Assessment of CAIX expression in p16-negative HNSCC could identify patients with the least favorable prognosis and inform therapeutic strategies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300470     DOI: 10.1016/j.ijrobp.2010.11.059

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  Cigarette Smoke Induces Metabolic Reprogramming of the Tumor Stroma in Head and Neck Squamous Cell Carcinoma.

Authors:  Marina Domingo-Vidal; Diana Whitaker-Menezes; Cristina Martos-Rus; Patrick Tassone; Christopher M Snyder; Madalina Tuluc; Nancy Philp; Joseph Curry; Ubaldo Martinez-Outschoorn
Journal:  Mol Cancer Res       Date:  2019-06-25       Impact factor: 5.852

3.  Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.

Authors:  Annette M Lim; Danny Rischin; Richard Fisher; Hongbin Cao; Kathleen Kwok; Daniel Truong; Grant A McArthur; Richard J Young; Amato Giaccia; Lester Peters; Quynh-Thu Le
Journal:  Clin Cancer Res       Date:  2011-11-17       Impact factor: 12.531

Review 4.  The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.

Authors:  Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb
Journal:  Antioxid Redox Signal       Date:  2014-05-09       Impact factor: 8.401

5.  Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.

Authors:  Nils H Nicolay; Nicole Wiedenmann; Michael Mix; Wolfgang A Weber; Martin Werner; Anca L Grosu; Gian Kayser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-07       Impact factor: 9.236

6.  Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.

Authors:  Joseph M Curry; Madalina Tuluc; Diana Whitaker-Menezes; Julie A Ames; Archana Anantharaman; Aileen Butera; Benjamin Leiby; David M Cognetti; Federica Sotgia; Michael P Lisanti; Ubaldo E Martinez-Outschoorn
Journal:  Cell Cycle       Date:  2013-04-10       Impact factor: 4.534

7.  Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Authors:  Helga Helseth Hektoen; Kjersti Flatmark; Yvonne Andersson; Svein Dueland; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  BMC Cancer       Date:  2015-07-24       Impact factor: 4.430

8.  The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma.

Authors:  A C Klimowicz; P Bose; S K Petrillo; A M Magliocco; J C Dort; N T Brockton
Journal:  Br J Cancer       Date:  2013-09-05       Impact factor: 7.640

9.  Identifying the stromal cell type that contributes to tumor aggressiveness associated with carbonic anhydrase IX.

Authors:  Pinaki Bose; Joseph C Dort; Nigel T Brockton
Journal:  Cell Cycle       Date:  2013-07-30       Impact factor: 4.534

Review 10.  Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review.

Authors:  Justin E Swartz; Ajit J Pothen; Inge Stegeman; Stefan M Willems; Wilko Grolman
Journal:  Cancer Med       Date:  2015-04-27       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.